Search research articles
Contact Us
Filters
Showing results (101-110 of 115) with videos related to
Page
of 12
Sort By:
Cells
|
April 26, 2024
Genomic Engineering of Oral Keratinocytes to Establish In Vitro Oral Potentially Malignant Disease Models as a Platform for Treatment Investigation
Leon J Wils, Marijke Buijze, Marijke Stigter-van Walsum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2006
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer
G A P Hospers, M Schaapveld, J W R Nortier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1996
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group
R C Coombes, J M Bliss, J Wils, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2003
Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952
C-H Köhne, J Wils, M Lorenz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2005
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986
C-H Köhne, E van Cutsem, J Wils, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2005
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG
D Nitti, J Wils, J Guimaraes Dos Santos, et al.
Anti-Cancer Drugs
|
May 18, 1999
Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg
J Wils, H van Geuns, J Stoot, et al.
Resuscitation
|
April 18, 2020
A cross-sectional investigation of communication in Do-Not-Resuscitate orders in Dutch hospitals
M Schluep, S E Hoeks, H Endeman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 22, 1999
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
E Van Cutsem, D Cunningham, W W Ten Bokkel Huinink, et al.
Anti-Cancer Drugs
|
March 23, 2001
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study
F Duffaud, M E van der Burg, M Namer, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 115) with videos related to
Sort By:
Page
of 12
Cells
|
April 26, 2024
Genomic Engineering of Oral Keratinocytes to Establish In Vitro Oral Potentially Malignant Disease Models as a Platform for Treatment Investigation
Leon J Wils, Marijke Buijze, Marijke Stigter-van Walsum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2006
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer
G A P Hospers, M Schaapveld, J W R Nortier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1996
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group
R C Coombes, J M Bliss, J Wils, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2003
Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952
C-H Köhne, J Wils, M Lorenz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2005
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986
C-H Köhne, E van Cutsem, J Wils, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2005
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG
D Nitti, J Wils, J Guimaraes Dos Santos, et al.
Anti-Cancer Drugs
|
May 18, 1999
Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg
J Wils, H van Geuns, J Stoot, et al.
Resuscitation
|
April 18, 2020
A cross-sectional investigation of communication in Do-Not-Resuscitate orders in Dutch hospitals
M Schluep, S E Hoeks, H Endeman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 22, 1999
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
E Van Cutsem, D Cunningham, W W Ten Bokkel Huinink, et al.
Anti-Cancer Drugs
|
March 23, 2001
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study
F Duffaud, M E van der Burg, M Namer, et al.
Page
of 12